ALK and non-small cell lung carcinoma: However, recently, Dietz et al. combined targeted NGS with copy number variation profiling using the shallow whole genome sequencing (sWGS) of ctDNA in order to improve the longitudinal monitoring of ALK-positive NSCLC patients in particular for cases without detectable mutations in ctDNA or with a wide range of acquired genomic alterations during therapy [191].